Literature DB >> 21958502

The opportunity cost of cancer care: a statement from NICE.

Michael D Rawlins1, Kalipso Chalkidou.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21958502     DOI： 10.1016/S1470-2045(11)70218-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.

Authors:  Andrea Messori
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

2.  The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil.

Authors:  Wânia Cristina da Silva; Brian Godman; Francisco de Assis Acúrcio; Mariângela Leal Cherchiglia; Antony Martin; Konrad Maruszczyk; Jans Bastos Izidoro; Marcos André Portella; Agner Pereira Lana; Orozimbo Henriques Campos Neto; Eli Iola Gurgel Andrade
Journal:  Appl Health Econ Health Policy       Date:  2021-01-28       Impact factor: 2.561

3.  Ethical Hurdles in the Prioritization of Oncology Care.

Authors:  Folkert de Groot; Stefano Capri; Jean-Claude Castanier; David Cunningham; Bruno Flamion; Mathias Flume; Harald Herholz; Lars-Åke Levin; Oriol Solà-Morales; Christoph J Rupprecht; Natalie Shalet; Andrew Walker; Olivier Wong
Journal:  Appl Health Econ Health Policy       Date:  2017-04       Impact factor: 2.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.